Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes

Abstract

Background: In short-term randomized trials (duration, 1 to 2 years), bariatric surgery has been associated with improvement in type 2 diabetes mellitus.

Methods: We assessed outcomes 3 years after the randomization of 150 obese patients with uncontrolled type 2 diabetes to receive either intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy. The primary end point was a glycated hemoglobin level of 6.0% or less.

Results: The mean (±SD) age of the patients at baseline was 48±8 years, 68% were women, the mean baseline glycated hemoglobin level was 9.3±1.5%, and the mean baseline body-mass index (the weight in kilograms divided by the square of the height in meters) was 36.0±3.5. A total of 91% of the patients completed 36 months of follow-up. At 3 years, the criterion for the primary end point was met by 5% of the patients in the medical-therapy group, as compared with 38% of those in the gastric-bypass group (P<0.001) and 24% of those in the sleeve-gastrectomy group (P=0.01). The use of glucose-lowering medications, including insulin, was lower in the surgical groups than in the medical-therapy group. Patients in the surgical groups had greater mean percentage reductions in weight from baseline, with reductions of 24.5±9.1% in the gastric-bypass group and 21.1±8.9% in the sleeve-gastrectomy group, as compared with a reduction of 4.2±8.3% in the medical-therapy group (P<0.001 for both comparisons). Quality-of-life measures were significantly better in the two surgical groups than in the medical-therapy group. There were no major late surgical complications.

Conclusions: Among obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical therapy alone. Analyses of secondary end points, including body weight, use of glucose-lowering medications, and quality of life, also showed favorable results at 3 years in the surgical groups, as compared with the group receiving medical therapy alone. (Funded by Ethicon and others; STAMPEDE ClinicalTrials.gov number, NCT00432809.).

Conflict of interest statement

No other potential conflict of interest relevant to this article was reported.

Figures

Figure 1. Mean Changes in Measures of Diabetes Control from Baseline to 3 Years

Shown are the percentage change in glycated hemoglobin levels (Panel A), the percentage change in glycated hemoglobin levels according to body-mass index (BMI) (Panel B), the average number of diabetes medications during the study period (Panel C), and the changes in BMI (Panel D) over a 3-year period among patients receiving intensive medical therapy only, sleeve gastrectomy, or gastric bypass. I bars indicate standard errors. Mean values in each group are provided below the graphs; in Panels A and B, median values are also provided in parentheses. P values are for the comparison between each surgical group and the medical-therapy group in Panels A, C, and D. In Panel B, P = 0.008 for the comparison between the surgical groups and the medical-therapy group for the subgroup of patients with a BMI of less than 35; P

Figure 2. Polar Chart of Scores for Quality of Life at Baseline and 3 Years after Randomization

The scores on the RAND 36-Item Health Survey range from the worst score of 0 (poor health) to the best score of 100 (good health). Asterisks indicate P